{"id":104156,"date":"2026-07-16T13:21:12","date_gmt":"2026-07-16T13:21:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/104156\/"},"modified":"2026-07-16T13:21:12","modified_gmt":"2026-07-16T13:21:12","slug":"roche-holding-swxrop-could-be-7-undervalued-on-pipeline-momentum","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/104156\/","title":{"rendered":"Roche Holding (SWX:ROP) Could Be 7% Undervalued On Pipeline Momentum"},"content":{"rendered":"\n

Make better investment decisions<\/a> with Simply Wall St’s easy, visual tools that give you a competitive edge. <\/p>\n

Roche Holding (SWX:ROP) is back in focus after the US Food and Drug Administration granted Priority Review to its supplemental Biologics License Application for Gazyva\/Gazyvaro in primary membranous nephropathy, highlighting late stage pipeline momentum. <\/p>\n

See our latest analysis for Roche Holding.<\/a> <\/p>\n

Roche Holding’s CHF330.2 share price follows a 5.33% 90 day share price return and a 32.83% 1 year total shareholder return, suggesting recent FDA and diagnostics news is feeding into building momentum rather than fading interest. <\/p>\n

If treatments and diagnostics in kidney and liver disease are on your radar, it could be a good moment to scan other opportunities using the healthcare focused 128 healthcare AI stocks<\/a> <\/p>\n

Roche Holding’s strong recent run sits at the crossroads of fresh excitement around its pipeline and a reassessment of its core pharma and diagnostics cash generation. How does that mix compare with what you are paying today? <\/p>\n

Most Popular Narrative: 6.5% Undervalued <\/p>\n

Roche Holding’s narrative fair value of CHF353.34 sits above the current CHF330.2 share price, pointing to a modest valuation gap built on cash flow strength and pipeline expectations. <\/p>\n

Roche is a high-quality, cash-generative pharma leader with: <\/p>\n

\u2705 Strong fundamentals: <\/p>\n

\u2022 $80B revenue scale <\/p>\n

\u2022 ~$26B EBITDA <\/p>\n

\u2022 ~30% margins <\/p>\n

\u2705 Attractive profile: <\/p>\n

\u2022 Defensive and dividend (~3%) <\/p>\n

\u2022 Deep pipeline with multiple catalysts <\/p>\n

Read the complete narrative.<\/a> <\/p>\n

Curious what sits behind that fair value for Roche Holding? The narrative leans heavily on steady revenue growth, firm margins and a future earnings multiple that assumes the current pipeline keeps delivering. The exact mix of those inputs might surprise you. <\/p>\n

Result: Fair Value of CHF353.34 (UNDERVALUED) <\/p>\n

Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n

However, this Roche Holding narrative still hinges on late stage pipeline delivery and exposure to biosimilar pressure, either of which could quickly change sentiment. <\/p>\n

Find out about the key risks to this Roche Holding narrative.<\/a> <\/p>\n

Next Steps <\/p>\n

If this Roche Holding story seems finely balanced between opportunity and concern, consider reviewing the figures promptly and comparing them with your own perspective by weighing the 5 key rewards and 1 important warning sign <\/p>\n

Looking for more investment ideas beyond Roche Holding? <\/p>\n

Do not stop at Roche Holding. Broaden your watchlist with other stocks that match your risk appetite, income goals, and quality filters using the Simply Wall Street Screener. <\/p>\n","protected":false},"excerpt":{"rendered":"Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Roche…\n","protected":false},"author":2,"featured_media":104157,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[2361,134,994,842],"class_list":["post-104156","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-investment-decisions","tag-roche","tag-roche-holding","tag-share-price"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116929867506762101","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/104156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=104156"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/104156\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/104157"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=104156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=104156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=104156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}